|
1
|
Oberndorfer S: Karzinoide tumoren des
dünndarms. In: Frankfurter Zeitschrift für Pathologie, pp426-429,
1907.
|
|
2
|
Gill AJ: Why did they change that?
Practical implications of the evolving classification of
neuroendocrine tumours of the gastrointestinal tract.
Histopathology. 78:162–170. 2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Guadagno E, D'Avella E, Cappabianca P,
Colao A and Del Basso De Caro M: Ki67 in endocrine neoplasms: To
count or not to count, this is the question! A systematic review
from the English language literature. J Endocrinol Invest.
43:1429–1445. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Assarzadegan N and Montgomery E: What is
new in the 2019 World Health Organization (WHO) classification of
tumors of the digestive system: Review of selected updates on
neuroendocrine neoplasms, appendiceal tumors, and molecular
testing. Arch Pathol Lab Med. 145:664–677. 2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Zappalà G, McDonald PG and Cole SW: Tumor
dormancy and the neuroendocrine system: An undisclosed connection?
Cancer Metastasis Rev. 32:189–200. 2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ramírez-Rentería C, Ferreira-Hermosillo A,
Marrero-Rodríguez D, Taniguchi-Ponciano K, Melgar-Manzanilla V and
Mercado M: An update on gastroenteropancreatic neuroendocrine
neoplasms: From mysteries to paradigm shifts. Arch Med Res.
51:765–776. 2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Klöppel G and La Rosa S: Ki67 labeling
index: Assessment and prognostic role in gastroenteropancreatic
neuroendocrine neoplasms. Virchows Arch. 472:341–349.
2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kim JY, Hong SM and Ro JY: Recent updates
on grading and classification of neuroendocrine tumors. Ann Diagn
Pathol. 29:11–16. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Chauhan A, Yu Q, Ray N, Farooqui Z, Huang
B, Durbin EB, Tucker T, Evers M, Arnold S and Anthony LB: Global
burden of neuroendocrine tumors and changing incidence in Kentucky.
Oncotarget. 9:19245–19254. 2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Sackstein PE, O'Neil DS, Neugut AI, Chabot
J and Fojo T: Epidemiologic trends in neuroendocrine tumors: An
examination of incidence rates and survival of specific patient
subgroups over the past 20 years. Semin Oncol. 45:249–258.
2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Riihimäki M, Hemminki A, Sundquist K,
Sundquist J and Hemminki K: The epidemiology of metastases in
neuroendocrine tumors. Int J Cancer. 139:2679–2686. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Akimoto J, Fukuhara H, Suda T, Nagai K,
Ichikawa M, Fukami S, Kohno M, Matsubayashi J and Nagao T:
Clinicopathological analysis in patients with neuroendocrine tumors
that metastasized to the brain. BMC Cancer. 16(36)2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Cives M, Quaresmini D, Rizzo FM, Felici C,
D'Oronzo S, Simone V and Silvestris F: Osteotropism of
neuroendocrine tumors: Role of the CXCL12/ CXCR4 pathway in
promoting EMT in vitro. Oncotarget. 8:22534–22549. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Cives M, Pellè E, Rinzivillo M, Prosperi
D, Tucci M, Silvestris F and Panzuto F: Bone metastases in
neuroendocrine tumors: Molecular parhogenesis and implications in
clinical practice. Neuroendocrinology. 111:207–216. 2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Harvey NC, McCloskey EV, Mitchell PJ,
Dawson-Hughes B, Pierroz DD, Reginster JY, Rizzoli R, Cooper C and
Kanis JA: Mind the (treatment) gap: A global perspective on current
and future strategies for prevention of fragility fractures.
Osteoporos Int. 28:1507–1529. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Liu J, Curtis EM, Cooper C and Harvey NC:
State of the art in osteoporosis risk assessment and treatment. J
Endocrinol Invest. 42:1149–1164. 2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Kanis JA, Svedbom A, Harvey N and
McCloskey EV: The osteoporosis treatment gap. J Bone Miner Res.
29:1926–1928. 2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
International Osteoporosis Foundation:
https://www.osteoporosis.foundation/. Accessed April
1, 2021.
|
|
19
|
Clynes MA, Harvey NC, Curtis EM, Fuggle
NR, Dennison EM and Cooper C: The epidemiology of osteoporosis. Br
Med Bull. 133:105–117. 2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Curtis EM, Woolford S, Holmes C, Cooper C
and Harvey NC: General and specific considerations as to why
osteoporosis-related care is often suboptimal. Curr Osteoporos Rep.
18:38–46. 2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Barton DW, Behrend CJ and Carmouche JJ:
Rates of osteoporosis screening and treatment following vertebral
fracture. Spine J. 19:411–417. 2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Söreskog E, Borgström F, Shepstone L,
Clarke S, Cooper C, Harvey I, Harvey NC, Howe A, Johansson H,
Marshall T, et al: Long-term cost-effectiveness of screening for
fracture risk in a UK primary care setting: the SCOOP study.
Osteoporos Int. 31:1499–1506. 2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Zamborsky R, Svec A, Kokavec M and Galbavy
S: Bone metastases in neuroendocrine tumors. Bratisl Lek Listy.
118:529–534. 2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Koizumi M, Gokita T and Toda K: Impending
atypical femoral fracture in patients with medullary thyroid cancer
with skeletal metastasis treated with long-term bisphosphonate and
denosumab. Clin Nucl Med. 42:463–464. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Carsote M, Valea A, Dumitru N, Terzea D,
Petrova E, Albu S, Buruiana A and Ghemigian A: Metastases in daily
endocrine practice. Arch Balk Med Union. 51:476–480. 2016.
|
|
26
|
Rizzo FM, Vesely C, Childs A, Marafioti T,
Khan MS, Mandair D, Cives M, Ensell L, Lowe H, Akarca AU, et al:
Circulating tumour cells and their association with bone metastases
in patients with neuroendocrine tumours. Br J Cancer. 120:294–300.
2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Zheng Z, Chen C, Jiang L, Zhou X, Dai X,
Song Y and Li Y: Incidence and risk factors of gastrointestinal
neuroendocrine neoplasm metastasis in liver, lung, bone, and brain:
A population-based study. Cancer Med. 8:7288–7298. 2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Van Loon K, Zhang L, Keiser J, Carrasco C,
Glass K, Ramirez MT, Bobiak S, Nakakura EK, Venook AP, Shah MH and
Bergsland EK: Bone metastases and skeletal-related events from
neuroendocrine tumors. Endocr Connect. 4:9–17. 2015.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Hori T, Yasuda T, Suzuki K, Kanamori M and
Kimura T: Skeletal metastasis of carcinoid tumors: Two case reports
and review of the literature. Oncol Lett. 3:1105–1108.
2012.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Trikalinos NA, Tan BR, Amin M, Liu J,
Govindan R and Morgensztern D: Effect of metastatic site on
survival in patients with neuroendocrine neoplasms (NENs). An
analysis of SEER data from 2010 to 2014. BMC Endocr Disord.
20(44)2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Wang S and Zhang J, Liu S and Zhang J: The
prognostic analysis of different metastatic patterns in pancreatic
neuroendocrine tumors patients: A population based analysis.
Medicine (Baltimore). 98(e17773)2019.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Deleval N, Pesque L, Dieudonné A, Viry F,
Hentic O, Lebtahi R, Ruszniewski P and de Mestier L: Prognostic
impact of bone metastases detected by 18F-DOPA PET in
patients with metastatic midgut neuroendocrine tumors. Eur Radiol.
31:4166–4174. 2021.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Altieri B, Di Dato C, Modica R,
Bottiglieri F, Di Sarno A, Pittaway JFH, Martini C, Faggiano A and
Colao A: Bone metabolism and vitamin D implication in
gastroenteropancreatic neuroendocrine tumors. Nutrients.
12(1021)2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Sen Gupta P, Grozinsky-Glasberg S, Drake
WM, Akker SA, Perry L, Grossman AB and Druce MR: Are serotonin
metabolite levels related to bone mineral density in patients with
neuroendocrine tumours? Clin Endocrinol (Oxf). 80:246–252.
2014.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Jacobson A and Cunningham JL: Connective
tissue growth factor in tumor pathogenesis. Fibrogenesis Tissue
Repair. 5 (Suppl 1)(S8)2012.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Migut AE, Kaur H and Avritscher R:
Neuroendocrine tumors: Imaging of treatment and follow-up. Radiol
Clin North Am. 58:1161–1171. 2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Galgano SJ, Sharbidre K and Morgan DE:
Multimodality imaging of neuroendocrine tumors. Radiol Clin North
Am. 58:1147–1159. 2020.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Albu SE, Geleriu A, Carsote M, Mihai A,
Vasiliu C and Poiana C: The vitamin D status in menopausal women.
Arch Balk MedUnion. 50:275–277. 2015.
|
|
39
|
Khashayar P, Meybodi HA, Amoabediny G and
Larijani B: Biochemical markers of bone turnover and their role in
osteoporosis diagnosis: A narrative review. Recent Pat Endocr Metab
Immune Drug Discov. 9:79–89. 2015.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Centre for Metabolic Bone Diseases,
University of Sheffield, UK: FRAX® Fracture Risk
Assessment Tool: https://www.sheffield.ac.uk/FRAX/tool.aspx?country=9.
Accessed April 1, 2021.
|
|
41
|
Carsote M, Radu O, Dumitrascu A, Terzea D,
Valea A and Ghemigian A: Bone and menopause: Threshold of
intervention. Rom Med J. 63:233–236. 2016.
|
|
42
|
Sandru F, Carsote M, Albu SE, Valea A,
Petca A and Dumitrascu MC: Glucagonoma: From skin lesions to the
neuroendocrine component (Review). Exp Ther Med. 20:3389–3393.
2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Byun J, Kim SH, Jeong HS, Rhee Y, Lee WJ
and Kang CM: ACTH-producing neuroendocrine tumor of the pancreas: A
case report and literature review. Ann Hepatobiliary Pancreat Surg.
21:61–65. 2017.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Sandru F, Carsote M, Dumitrascu MC, Albu
SE and Valea A: Glucocorticoids and trabecular bone score. J Med
Life. 13:449–453. 2020.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Kannivelu A, Loke KS, Kok TY, Osmany SY,
Ali SZ, Suat-Jin L and Ng DC: The role of PET/CT in the evaluation
of skeletal metastases. Semin Musculoskelet Radiol. 18:149–165.
2014.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Adkins J and Lu Y: Diffuse bone metastases
in pancreatic neuroendocrine tumor shown on octreoscan. Clin Nucl
Med. 44:257–258. 2019.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Gauthé M, Testart Dardel N, Ruiz Santiago
F, Ohnona J, Nataf V, Montravers F and Talbot JN: Vertebral
metastases from neuroendocrine tumours: How to avoid false
positives on 68Ga-DOTA-TOC PET using CT pattern
analysis? Eur Radiol. 28:3943–3952. 2018.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Lim KHJ, Raja H, D'Arienzo P, Barriuso J,
McNamara MG, Hubner RA, Mansoor W, Valle JW and Lamarca A:
Identification of areas for improvement in the management of bone
metastases in patients with neuroendocrine neoplasms.
Neuroendocrinology. 110:688–696. 2020.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Altieri B, Di Dato C, Martini C,
Sciammarella C, Di Sarno A, Colao A and Faggiano A: NIKE Group.
Bone metastases in neuroendocrine neoplasms: From pathogenesis to
clinical management. Cancers (Basel). 11(1332)2019.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Alexandraki KI, Pizanias M, Uri I, Thomas
D, Page T, Kolomodi D, Low CS, Adesanya O, Tsoli M, Gross DJ, et
al: The prognosis and management of neuroendocrine
neoplasms-related metastatic bone disease: Lessons from clinical
practice. Endocrine. 64:690–701. 2019.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Zhang M, Zhao P, Shi X, Zhao A, Zhang L
and Zhou L: Clinicopathological features and prognosis of
gastroenteropancreatic neuroendocrine neoplasms in a Chinese
population: A large, retrospective single-centre study. BMC Endocr
Disord. 17(39)2017.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Helbig G, Straczyńska-Niemiec A, Szewczyk
I, Nowicka E, Bierzyńska-Macyszyn G and Kyrcz-Krzemień S:
Unexpected cause of anemia: Metastasis of neuroendocrine tumor to
the bone marrow. Pol Arch Med Wewn. 124:635–636. 2014.PubMed/NCBI
|
|
53
|
Valea A, Carsote M, Ghervan C and
Georgescu C: Glycemic profile in patients with acromegaly treated
with somatostatin analogue. J Med Life. 8:82–86. 2015.PubMed/NCBI
|
|
54
|
Lamarca A, Elliott E, Barriuso J, Backen
A, McNamara MG, Hubner R and Valle JW: Chemotherapy for advanced
non-pancreatic well-differentiated neuroendocrine tumours of the
gastrointestinal tract, a systematic review and meta-analys: A lost
cause? Cancer Treat Rev. 44:26–41. 2016.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Poiană C, Carşote M, Ardeleanu C, Terzea
D, Avramescu ET, Neamţu MC and Miulescu RD: The value of the
immunohistochemistry in a case of gastric neuroendocrine tumor and
thyroid metastasis. Rom J Morphol Embryol. 52:187–192.
2011.PubMed/NCBI
|
|
56
|
Watts NB: Postmenopausal osteoporosis: A
clinical review. J Womens Health (Larchmt). 27:1093–1096.
2018.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Misiorowski W: Osteoporosis in men. Prz
Menopauzalny. 16:70–73. 2017.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Cortellini A, Bozzetti F, Palumbo P,
Brocco D, Di Marino P, Tinari N, De Tursi M, Agostinelli V, Patruno
L, Valdesi C, et al: Weighing the role of skeletal muscle mass and
muscle density in cancer patients receiving PD-1/PD-L1 checkpoint
inhibitors: A multicenter real-life study. Sci Rep.
10(1456)2020.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Fernández-Sala X, Barceló-Vidal J,
Tusquets I and Conde-Estévez D: Effectiveness and safety of a novel
dexamethasone mouthwash formulation in managing stomatitis in
cancer patients. Farm Hosp. 45:41–44. 2020.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Conteduca V, Oromendia C, Eng KW, Bareja
R, Sigouros M, Molina A, Faltas BM, Sboner A, Mosquera JM, Elemento
O, et al: Clinical features of neuroendocrine prostate cancer. Eur
J Cancer. 121:7–18. 2019.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Clement DS, Tesselaar ME, van Leerdam ME,
Srirajaskanthan R and Ramage JK: Nutritional and vitamin status in
patients with neuroendocrine neoplasms. World J Gastroenterol.
25:1171–1184. 2019.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Kędzierska L, Madej-Michniewicz A, Marczuk
N, Dołęgowska B, Starzyńska T and Błogowski W: Clinical
significance of various growth factors in patients with different
gastric neoplasms. Am J Transl Res. 12:118–129. 2020.PubMed/NCBI
|
|
63
|
Ranade R and Basu S: Metabolic bone
disease in the context of metastatic neuroendocrine tumor:
Differentiation from skeletal metastasis, the molecular PET-CT
imaging features, and exploring the possible etiopathologies
including parathyroid adenoma (MEN1) and paraneoplastic humoral
hypercalcemia of malignancy due to PTHrP hypersecretion. World J
Nucl Med. 16:62–67. 2017.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Iliesiu A, Ungureanu IA, Petca A,
Constantin MM, Petca RC, Sandru F, Constantin T and Dumitrascu MC:
Paraganglioma presenting as a mesenteric cystic mass: A case
report. Exp Ther Med. 20:2489–2492. 2020.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Valea A, Morar A, Ghemigian A, Petrova E,
Tupea C, Popescu M, Dumitru N and Carsote M: Diagnosis of
neurofibromatosis type 1-related pheocromocytoma after stroke and
myocardical infarction. Rom Med J. 67:420–424. 2020.
|
|
66
|
Aygun N and Uludag M: Pheochromocytoma and
paraganglioma: From epidemiology to clinical findings. Sisli Etfal
Hastan Tip Bul. 54:159–168. 2020.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Sandru F, Dumitrascu MC, Albu SE, Carsote
M and Valea A: Osteoporosis and adrenal incidentaloma: To be or not
to be? Rom J Med Pract. 14:381–384. 2019.
|
|
68
|
Jimenez P, Tatsui C, Jessop A, Thosani S
and Jimenez C: Treatment for malignant pheochromocytomas and
paragangliomas: 5 Years of progress. Curr Oncol Rep.
19(83)2017.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Ilanchezhian M, Jha A, Pacak K and Del
Rivero J: Emerging treatments for advanced/metastatic
pheochromocytoma and paraganglioma. Curr Treat Options Oncol.
21(85)2020.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Rider AJ, Walsh A, Sollenberger EL, Dryden
SC, DeAngelis KD, Weir AB III and Fowler BT: Orbital
pheochromocytoma metastasis in 2 patients with known
pheochromocytoma. Ophthalmic Plast Reconstr Surg. 35:e131–e134.
2019.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Rahpeyma A and Khajehahmadi S:
Pheochromocytoma metastasing to the jaw: Review of the literature
and new case. Indian J Surg Oncol. 11:433–437. 2020.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Fadiga L, Saraiva J, Paiva I and Carrilho
F: Thoracic spine metastasis presenting 18 years after complete
resection of a phaeochromocytoma. BMJ Case Rep.
12(e229621)2019.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Jang Khan NA, Ullah S, Siddiqui HU and
Karim A: Spinal cord compression by metastatic thoracic spine
paraganglioma. J Ayub Med Coll Abbottabad. 28:617–619.
2016.PubMed/NCBI
|
|
74
|
Ayala-Ramirez M, Palmer JL, Hofmann MC, de
la Cruz M, Moon BS, Waguespack SG, Habra MA and Jimenez C: Bone
metastases and skeletal-related events in patients with malignant
pheochromocytoma and sympathetic paraganglioma. J Clin Endocrinol
Metab. 98:1492–1497. 2013.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Huang CT, Yang WC and Lin SF: Multiple
endocrine neoplasia type 2A. Kaohsiung J Med Sci. 28:341–344.
2012.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Gravel G, Leboulleux S, Tselikas L, Fassio
F, Berraf M, Berdelou A, Ba B, Hescot S, Hadoux J, Schlumberger M,
et al: Prevention of serious skeletal-related events by
interventional radiology techniques in patients with malignant
paraganglioma and pheochromocytoma. Endocrine. 59:547–554.
2018.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Athimulam S and Bancos I: Evaluation of
bone health in patients with adrenal tumors. Curr Opin Endocrinol
Diabetes Obes. 26:125–132. 2019.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Kim BJ, Kwak MK, Kim JS, Lee SH and Koh
JM: Higher sympathetic activity as a risk factor for skeletal
deterioration in pheochromocytoma. Bone. 116:1–7. 2018.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Yokomoto-Umakoshi M, Umakoshi H, Fukumoto
T, Matsuda Y, Nagata H, Ogata M, Kawate H, Miyazawa T, Sakamoto R
and Ogawa Y: Q-AND-A study group. Pheochromocytoma and
paraganglioma: An emerging cause of secondary osteoporosis. Bone.
133(115221)2020.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Yokomoto-Umakoshi M, Umakoshi H, Sakamoto
R, Fukumoto T, Ogata M, Nakano Y, Iwahashi N, Kaneko H, Mizoguchi
N, Hattori A, et al: Role of deteriorated bone quality in the
development of osteoporosis in pheochromocytoma and paraganglioma.
Bone. 142(115607)2021.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Yokomoto-Umakoshi M, Umakoshi H, Ogata M,
Fukumoto T, Matsuda Y, Miyazawa T, Sakamoto R and Ogawa Y: Q-AND-A
study group. Coexistence of osteoporosis and atherosclerosis in
pheochromocytoma: New insights into its long-term management.
Osteoporos Int. 31:2151–2160. 2020.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Poiana C, Radoi V, Carsote M and
Bilezikian JP: New clues that may link osteoporosis to the
circulating lipid profile. Bone Res. 1:260–266. 2013.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Jackuliak P, Kužma M, Killinger Z and
Payer J: Good long-term glycemic compensation is associated with
better trabecular bone score in postmenopausal women with type 2
diabetes. Physiol Res. 68 (Suppl 2):S149–S156. 2019.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Webb SM and Valassi E: Morbidity of
Cushing's syndrome and impact of treatment. Endocrinol Metab Clin
North Am. 47:299–311. 2018.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Dumitrascu MC, Stanescu AMA, Bejan C,
Sandru F, Toader DO, Radavoi DG, Cotirlet A, Judea Pusta CT and
Diaconu CC: Obesity and its implications on stress urinary
incontinence. Rev Chim. 70:3660–3662. 2019.
|
|
86
|
Young J, Haissaguerre M, Viera-Pinto O,
Chabre O, Baudin E and Tabarin A: Management of endocrine disease:
Cushing's syndrome due to ectopic ACTH secretion: An expert
operational opinion. Eur J Endocrinol. 182:R29–R58. 2020.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Grigoryan S, Avram AM and Turcu AF:
Functional imaging in ectopic Cushing syndrome. Curr Opin
Endocrinol Diabetes Obes. 27:146–154. 2020.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Kyriacou A, Stepien KM and Issa B: Urinary
steroid metabolites in a case of florid ectopic Cushing's syndrome
and clinical correlations. Hormones (Athens). 15:540–547.
2016.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Hayes AR and Grossman AB: The ectopic
adrenocorticotropic hormone syndrome: Rarely easy, always
challenging. Endocrinol Metab Clin North Am. 47:409–425.
2018.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Șandru F, Dumitrașcu MC, Albu SE, Carsote
M and Valea A: Obesity and osteoporotic fractures. Rom J Mil Med.
123:166–171. 2020.
|
|
91
|
Carsote M, Preda SA, Mitroi M, Camen A and
Radu L: Serum osteocalcin, P1NP, alkaline phosphase, and crosslaps
in humans: The relationship with body mass index. Rev Chim.
70:1615–1618. 2019.
|
|
92
|
Broersen LHA, van Haalen FM, Kienitz T,
Biermasz NR, Strasburger CJ, Dekkers OM and Pereira AM: Sex
Differences in presentation but not in outcome for ACTH-dependent
Cushing's syndrome. Front Endocrinol (Lausanne). 10(580)2019.
|
|
93
|
Vinolas H, Grouthier V, Mehsen-Cetre N,
Boisson A, Winzenrieth R, Schaeverbeke T, Mesguich C, Bordenave L
and Tabarin A: Assessment of vertebral microarchitecture in overt
and mild Cushing's syndrome using trabecular bone score. Clin
Endocrinol (Oxf). 89:148–154. 2018.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Valassi E, Santos A, Yaneva M, Tóth M,
Strasburger CJ, Chanson P, Wass JA, Chabre O, Pfeifer M, Feelders
RA, et al: The European registry on Cushing's syndrome: 2-Year
experience. Baseline demographic and clinical characteristics. Eur
J Endocrinol. 165:383–392. 2011.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Rashid F, Riccio SA, Munk PL, Malfair D
and Heran MK: Vertebroplasty for vertebral compression fractures
secondary to Cushing's syndrome induced by an ACTH-producing
bronchial carcinoid tumour. Singapore Med J. 50:e147–e150.
2009.PubMed/NCBI
|
|
96
|
Coe SG, Tan WW and Fox TP: Cushing's
syndrome due to ectopic adrenocorticotropic hormone production
secondary to hepatic carcinoid: Diagnosis, treatment, and improved
quality of life. J Gen Intern Med. 23:875–878. 2008.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Neary NM, Lopez-Chavez A, Abel BS, Boyce
AM, Schaub N, Kwong K, Stratakis CA, Moran CA, Giaccone G and
Nieman LK: Neuroendocrine ACTH-producing tumor of the
thymus-experience with 12 patients over 25 years. J Clin Endocrinol
Metab. 97:2223–2230. 2012.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Gut P: Liver metastases in
gastroenteropancreatic neuroendocrine tumours-treatment methods.
Prz Gastroenterol. 15:207–214. 2020.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Carsote M, Petrova EN, Radu O, Goldstein
A, Ghemigian A and Valea A: Serotonin: Beyond menopause: Rom J Med
Pract (Pract Med). 11:270–272. 2016.
|
|
100
|
Szajer J, Yung G, Russo R and Mansberg R:
Adrenocorticotropic hormone-secreting neuroendocrine tumor of the
rectum demonstrated on 68Ga-DOTATATE and 18F-FDG PET imaging. Clin
Nucl Med. 42:773–775. 2017.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Angarita FA, Rodríguez JL, Meek E, Sánchez
JO, Tawil M and Torregrosa L: Locally-advanced primary
neuroendocrine carcinoma of the breast: Case report and review of
the literature. World J Surg Oncol. 11(128)2013.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Banerjee SS and Eyden B: Divergent
differentiation in malignant melanomas: A review. Histopathology.
52:119–129. 2008.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Poiană C, Neamţu MC, Avramescu ET, Carşote
M, Trifănescu R, Terzea D, Neamţu OM and Dănciulescu Miulescu R:
The dedifferentiation of neuroendocrine tumor metastases: Myth or
reality? Rom J Morphol Embryol. 54:201–203. 2013.PubMed/NCBI
|
|
104
|
Dumas M, Laly P, Gottlieb J, Vercellino L,
Paycha F, Bagot M, Baroudjian B, Madelaine I, Basset-Seguin N,
Eftekhari P, et al: Osteopenia and fractures associated with
long-term therapy with MEK inhibitors. Melanoma Res. 28:641–644.
2018.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Lee YK, Lee EG, Kim HY, Lee Y, Lee SM, Suh
DC, Yoo JI and Lee S: Osteoporotic fractures of the spine, hip, and
other locations after adjuvant endocrine therapy with aromatase
inhibitors in breast cancer patients: A meta-analysis. J Korean Med
Sci. 35(e403)2020.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Li Y and Simonds WF: Endocrine neoplasms
in familial syndromes of hyperparathyroidism. Endocr Relat Cancer.
23:R229–R247. 2016.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Miulescu R, Balaban DV, Sandru F and Jinga
M: Cutaneous manifestations in pancreatic diseases-A review. J Clin
Med. 9(2611)2020.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Slouma M, Abbes M, Dhahri R, Litaiem N,
Gueddiche N, Mansouri N, Msekni I, Gharsallah I, Metoui L and
Louzir B: Multiple endocrine neoplasia type 1 revealed by a hip
pathologic fracture. Clin Rheumatol. 40:775–782. 2021.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Herath M, Parameswaran V, Thompson M,
Williams M and Burgess J: Paediatric and young adult manifestations
and outcomes of multiple endocrine neoplasia type 1. Clin
Endocrinol (Oxf). 91:633–638. 2019.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Mele C, Mencarelli M, Caputo M, Mai S,
Pagano L, Aimaretti G, Scacchi M, Falchetti A and Marzullo P:
Phenotypes associated with MEN1 syndrome: A focus on
genotype-phenotype correlations. Front Endocrinol (Lausanne).
11(591501)2020.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Sandru F, Carsote M, Valea A, Albu SE,
Petca RC and Dumitrascu MC: Somatostatinoma: Beyond
neurofibromatosis type 1 (review). Exp Ther Med. 20:3383–3388.
2020.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Shah S and George KJ: The association of
spinal deformity with dural ectasia in neurofibromatosis type 1. Br
J Neurosurgery. 33:620–623. 2019.PubMed/NCBI View Article : Google Scholar
|
|
113
|
Prudhomme L, Delleci C, Trimouille A,
Chateil JF, Prodhomme O, Goizet C and Van Gils J: Severe thoracic
and spinal bone abnormalities in neurofibromatosis type 1. Eur J
Med Genet. 63(103815)2020.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Eads JR, Reidy-Lagunes D, Soares HP, Chan
JA, Anthony LB, Halfdanarson TR, Naraev BG, Wolin EM, Halperin DM,
Li D, et al: Differential diagnosis of diarrhea in patients with
neuroendocrine tumors. Pancreas. 49:1123–1130. 2020.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Michalowska M, Znorko B, Kaminski T,
Oksztulska-Kolanek E and Pawlak D: New insights into tryptophan and
its metabolites in the regulation of bone metabolism. J Physiol
Pharmacol. 66:779–791. 2015.PubMed/NCBI
|
|
116
|
Al Saedi A, Sharma S, Summers MA, Nurgali
K and Duque G: The multiple faces of tryptophan in bone biology.
Exp Gerontol. 129(110778)2020.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Khanassov V, Hu J, Reeves D and van
Marwijk H: Selective serotonin reuptake inhibitor and selective
serotonin and norepinephrine reuptake inhibitor use and risk of
fractures in adults: A systematic review and meta-analysis. Int J
Geriatr Psychiatry. 33:1688–1708. 2018.PubMed/NCBI View Article : Google Scholar
|
|
118
|
Banskota S, Ghia JE and Khan WI: Serotonin
in the gut: Blessing or a curse. Biochimie. 161:56–64.
2019.PubMed/NCBI View Article : Google Scholar
|
